Skip to main content
$48.00 -$3.69 (-7.1%)

04:00 PM EDT on 09/20/21

Vericel Corporation (NASDAQ:VCEL)

CAPS Rating: 2 out of 5

The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.

Current Price $48.00 Mkt Cap $2.2B
Open $50.05 P/E Ratio 250.89
Prev. Close $48.00 Div. (Yield) $0.00 (0.0%)
Daily Range $46.50 - $50.36 Volume 457,173
52-Wk Range $17.78 - $68.94 Avg. Daily Vol. 341,219

Caps

How do you think NASDAQ:VCEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

112 Outperform
29 Underperform
 

All-Star Players

12 Outperform
8 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VCEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

AndrewGreenBull (92.13)
Submitted March 10, 2014

Earning will be released on Mar 13, phase 2 data of ixmyelocel-T for the treatment of dilated cardiomyopathy (DCM) probably will be released at the same time. It is due to release… More

zzlangerhans (99.06)
Submitted December 16, 2016

I'm a little late with my Vericel underperform pitch because I've been busy as Hell with real life short trades and making real money. It's been a good couple of days with Vericel, Brainstorm, Catalyst, and XBiotech eating some serious dirt after… More

NASDAQ:VCEL VS S&P 500 (SPY)

Fools bullish on NASDAQ:VCEL are also bullish on:

Fools bearish on NASDAQ:VCEL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VCEL.

Recs

0
Member Avatar TMFacarchidi (< 20) Submitted: 3/1/2021 11:32:39 AM : Outperform Start Price: $48.51 NASDAQ:VCEL Score: -13.20

Rapidly growing revenue.

Recs

0
Member Avatar Lakired (< 20) Submitted: 9/22/2017 6:44:57 PM : Outperform Start Price: $3.70 NASDAQ:VCEL Score: +1,120.69

VCEL is a buy on the strength of its growing MACI pipeline alone, but an extremely strong buy with two catalysts shortly upcoming. A licensing agreement with ICT to bring VCEL's innovations to the Chinese (and greater Asian) market will be processed in the very near future resulting in an influx of cash. The second catalyst is an anticipated green light from the FDA for accelerated approval of ixCELL. I got in at 3.6, but even at (or just under) 5 (and likely into the 6s) this is still a phenomenal investment with growth potential into the teens by 2018.

Recs

0
Member Avatar denniscerny (< 20) Submitted: 5/15/2017 9:36:01 AM : Outperform Start Price: $2.65 NASDAQ:VCEL Score: +1,631.58

Strong pipeline and positive developments.

Leaderboard

Find the members with the highest scoring picks in VCEL.

Score Leader

zzlangerhans

zzlangerhans (99.06) Score: +1,728.31

The Score Leader is the player with the highest score across all their picks in VCEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
denniscerny < 20 5/15/2017 Outperform 5Y $2.65 +1,713.37% +81.79% +1,631.58 1 Comment
zzlangerhans 99.06 3/22/2017 Outperform 1Y $2.65 +1,711.32% +86.29% +1,625.03 0 Comment
Under5 68.16 3/29/2017 Outperform 5Y $2.75 +1,645.45% +85.06% +1,560.40 0 Comment
jimbospix 77.37 3/3/2014 Outperform 5Y $3.34 +1,337.13% +136.07% +1,201.06 0 Comment
Lakired < 20 8/15/2017 Outperform 5Y $3.70 +1,197.30% +76.61% +1,120.69 1 Comment
ValueHunter09 < 20 8/18/2014 Outperform 5Y $3.61 +1,229.64% +121.01% +1,108.63 0 Comment
Ado69 54.19 3/17/2014 Outperform 5Y $3.60 +1,233.33% +135.02% +1,098.31 0 Comment
showmejp 78.93 11/12/2013 Outperform 5Y $3.66 +1,211.48% +146.51% +1,064.96 0 Comment
samdeva 59.37 3/11/2014 Outperform 5Y $3.91 +1,127.62% +131.47% +996.15 0 Comment
ajk0928 < 20 3/11/2016 Outperform 5Y $4.23 +1,034.75% +116.72% +918.03 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VCEL.